Showing 1,321 - 1,340 results of 1,447 for search '"liver diseases"', query time: 0.09s Refine Results
  1. 1321

    Characteristics of NAFLD Based on Hypopituitarism by Kazuhisa Kodama, Atsuhiro Ichihara, Yasufumi Seki, Yuichi Ikarashi, Takaomi Sagawa, Tomomi Kogiso, Maiko Taniai, Katsutoshi Tokushige

    Published 2020-01-01
    “…Hypopituitarism and hypothalamic disorders, which induce central obesity and appetite disorder, are associated with nonalcoholic fatty liver disease (NAFLD). We retrospectively analyzed the clinical features of NAFLD patients with hypopituitarism. …”
    Get full text
    Article
  2. 1322

    Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study by Chengfu Xu, Jinghua Wang, Xinyu Wang, Yishu Chen, Shenghui Chen, Haoliang Zhai

    Published 2022-06-01
    “…Participants with hyperuricaemia showed a higher prevalence of metabolic syndrome and fatty liver disease than participants with normouraemia. Age, waist circumference, estimated glomerular filtration rate, blood urea nitrogen, excessive drinking and fatty liver were associated with hyperuricaemia in both genders.Conclusion The prevalence of hyperuricaemia was 9.4% in non-obese Chinese adults. …”
    Get full text
    Article
  3. 1323

    Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response by T. M. Ignatova, T. N. Lopatkina, V. P. Chulanov, Ye. V. Gaydasheva, S. N. Batskikh, G. V. Mikhaylovskaya, D. T. Abdurakhmanov, S. Yu. Karpov, Ye. N. Nikulkina, O. A. Chernova

    Published 2013-09-01
    “…There were no cases of decompensation of LC, hepatocellular carcinoma and death due to liver disease.Conclusion. At patients who have achieved SVO as a result of AVT, late relapses of HCV-infection are rare and in the majority no disease progression was found. …”
    Get full text
    Article
  4. 1324

    Noninvasive Evaluation of Liver Function in Morbidly Obese Patients by Patrick H. Alizai, Isabella Lurje, Andreas Kroh, Sophia Schmitz, Tom Luedde, Julia Andruszkow, Ulf P. Neumann, Florian Ulmer

    Published 2019-01-01
    “…More than half of the obese patients develop nonalcoholic fatty liver disease (NAFLD), which may further progress to nonalcoholic steatohepatitis (NASH) and cirrhosis. …”
    Get full text
    Article
  5. 1325

    Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis by Xiangbo Xu, Fangbo Gao, Ting Wang, Zuyao Yang, Qingchun Zhao, Xingshun Qi

    Published 2024-12-01
    “…Subgroup meta-analyses were performed according to the proportions of ascites and Child-Pugh class B/C and the mean model for end-stage liver disease (MELD) score. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.Results Fourteen studies were finally included. …”
    Get full text
    Article
  6. 1326

    Evaluating body roundness index and systemic immune inflammation index for mortality prediction in MAFLD patients by Di Zeng, Qingyue Zeng, Shuangqing Li, Jiong Lu, Nansheng Cheng

    Published 2025-01-01
    “…Abstract Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major cause of liver-related morbidity and mortality, contributing to both cardiovascular and non-cardiovascular deaths. …”
    Get full text
    Article
  7. 1327

    Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice by Dongliang Chen, Yue Shen, Yue Shen, Fang Huang, Bo Huang, Shangfu Xu, Shangfu Xu, Lisheng Li, Lisheng Li, Jie Liu, Zheng Li, Xia Li

    Published 2025-01-01
    “…Modern pharmacological research has confirmed that Polygonum cyrtonema Hua is able to alleviate nonalcoholic fatty liver disease, but the precise mechanism requires further investigation. …”
    Get full text
    Article
  8. 1328

    Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction by Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho

    Published 2024-12-01
    “…Background Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. …”
    Get full text
    Article
  9. 1329

    Curvilinear association between Framingham Steatosis Index and chronic kidney disease: a nationwide cross-sectional study by Chunqi Jiang, Bo Wang, Jun Wang, Yinuo Qu, Xin Zhang, Xin Zhang

    Published 2025-01-01
    “…IntroductionFatty liver disease is potentially linked to chronic kidney disease (CKD), yet the association between the Framingham Steatosis Index (FSI) and CKD remains uncharted. …”
    Get full text
    Article
  10. 1330

    High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice by Eya Sellami, Paulo Henrique Evangelista-Silva, Caio Jordão Teixeira, Khoudia Diop, Patricia Mitchell, Fernando Forato Anhê

    Published 2025-03-01
    “…Objective: Increased fructose consumption contributes to type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), but the mechanisms are ill-defined. …”
    Get full text
    Article
  11. 1331

    Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis by Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang

    Published 2025-12-01
    “…Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. …”
    Get full text
    Article
  12. 1332

    Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage by Yong-fen Zhu, Jin Wang, Jia-zhui Fang, Qiao Yang, Fang-fang Lv

    Published 2020-01-01
    “…Patients with chronic hepatitis B (CHB) concomitant with nonalcoholic fatty liver disease (NAFLD) are increasing. Objectives. To identify pathological features that can be used to differentiate between chronic inflammation caused by CHB and that caused by NAFLD. …”
    Get full text
    Article
  13. 1333

    e-GLR Score Predicts Early Graft Loss in Adult Live-Donor Liver Transplantation by Viniyendra Pamecha, MS, MRCS, FRCS, FEBS, Nilesh Sadashiv Patil, MS, MCh, Tharun Gattu, MS, Guresh Kumar, MSc, MPhil, PhD, Bramhadatta Pattnaik, MS, MCh, Nihar Mohapatra, MS, MCh, Gaurav Sindwani, MD, PDCC, Ashok Choudhury, MD, DM

    Published 2023-12-01
    “…Multivariate logistic regression analysis determined donor age (P = 0.045), estimated (e) graft weight (P = 0.001), and the model for end-stage liver disease (MELD) score (0.001) as independent predictors of early graft loss due to EGD. …”
    Get full text
    Article
  14. 1334

    Unveiling the novel role of circadian rhythms in sepsis and septic shock: unexplored implications for chronotherapy by Stewart D. Ramsay, Stewart D. Ramsay, Stewart D. Ramsay, Marni A. Nenke, Marni A. Nenke, Emily J. Meyer, Emily J. Meyer, David J. Torpy, David J. Torpy, Richard L. Young, Richard L. Young, Richard L. Young, Richard L. Young

    Published 2025-02-01
    “…These disruptions misalign external cues to body processes and contribute to diseases such as obesity and non-alcoholic fatty liver disease. They also exacerbate pre-existing health issues, such as depression and inflammatory bowel disease. …”
    Get full text
    Article
  15. 1335
  16. 1336

    Chemical Characterization and Differential Lipid-Modulating Effects of Selected Plant Extracts from Côa Valley (Portugal) in a Cell Model for Liver Steatosis by Ricardo Amorim, Mário Pedro Marques, Catarina Melim, Carla Varela, Vilma A. Sardão, José Teixeira, Maria Inês Dias, Lillian Barros, Paulo J. Oliveira, Célia Cabral

    Published 2025-01-01
    “…Given their rich ethnomedicinal history, we evaluated their protective effects on an in vitro model of metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: Decoction (D) and hydroalcoholic (EtOH80%) extracts were prepared and chemically characterized. …”
    Get full text
    Article
  17. 1337

    Intravoxel Incoherent Motion (IVIM) Diffusion-Weighted Imaging (DWI) in Patients with Liver Dysfunction of Chronic Viral Hepatitis: Segmental Heterogeneity and Relationship with Ch... by Lei Ding, Lianxiang Xiao, Xiangtao Lin, Chunmei Xiong, Lingbo Lin, Shijun Chen

    Published 2018-01-01
    “…This was a retrospective study of 82 consecutive patients with chronic liver disease who underwent MRI examination at the Jinan Infectious Diseases Hospital between January 2015 and December 2016. …”
    Get full text
    Article
  18. 1338

    Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study by Ping Chen, Yang Zheng, Yubo Cai, Pengfei Zou, Nan Li, Conggao Peng, Hainv Gao, Jimin Liu, Yongping Chen, Zhaowei Tong, Lanjuan Li

    Published 2020-01-01
    “…Chronic HCV infection affects 80 million people globally and may progress to advanced liver disease. The present study aims to investigate the present epidemiology of HCV infection in a southeastern Chinese surgical patient cohort. …”
    Get full text
    Article
  19. 1339

    Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury by Farhin Patel, Kirti Parwani, Dhara Patel, Palash Mandal

    Published 2021-01-01
    “…Despite rigorous research, there is still no Food and Drug Administration (FDA) approved therapies for any stage of alcoholic liver disease (ALD). Interestingly, metformin (Met) and several probiotic strains possess the potential of inhibiting alcoholic liver injury. …”
    Get full text
    Article
  20. 1340

    Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway by Canghai Guan, Xinlei Zou, Wujiang Shi, Jianjun Gao, Chengru Yang, Yifei Ge, Zhaoqiang Xu, Shaowu Bi, Xiangyu Zhong

    Published 2025-01-01
    “…Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of metabolic dysfunction–associated fatty liver disease metabolic dysfunction-associated steatohepatitis , characterized by hepatic steatosis, inflammation, and fibrosis. …”
    Get full text
    Article